Solid Tumor Malignancy: Clinical Trials

1 trial for Solid Tumor Malignancy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Completed 1

Follow Solid Tumor Malignancy: new trials by email Literature Review of Solid Tumor Malignancy trials Research Report on Solid Tumor Malignancy

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG - Solid Tumor Malignancy, Hematologic Malignancy
Phase 2CompletedNational Cancer Institute (NCI)192021-04-282024-08-27

Narrower conditions

Hematologic Neoplasms (1)  ·  Leukemia (1)  ·  Lymphoma (1)  ·  Multiple Myeloma (1)

Broader conditions

Blood Protein Disorders (1)  ·  Cardiovascular Diseases (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Hemorrhagic Disorders (1)  ·  Hemostatic Disorders (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Lymphatic Diseases (1)  ·  Lymphoproliferative Disorders (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms by Site (1)  ·  Neoplasms, Plasma Cell (1)  ·  Paraproteinemias (1)

Interventions

2019-nCoV Vaccine mRNA-1273 (1)  ·  Anti-Bacterial Agents (1)  ·  Antiemetics (1)  ·  Antifungal Agents (1)  ·  Electrocardiography (1)  ·  RNA, Messenger (1)

Sponsors

National Cancer Institute (NCI) (1)

Countries

United States (1)

Top investigators

James Gulley, M.D. (1)